129 related articles for article (PubMed ID: 10883413)
1. Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations.
Andresen I; Kovarik JM; Spycher M; Bolli R
J Clin Pharmacol; 2000 Jul; 40(7):722-30. PubMed ID: 10883413
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
[TBL] [Abstract][Full Text] [Related]
3. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions.
Bolli R; Woodtli K; Bärtschi M; Höfferer L; Lerch P
Biologicals; 2010 Jan; 38(1):150-7. PubMed ID: 19931468
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
6. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency.
Kallenberg CG
Clin Exp Immunol; 2007 Dec; 150(3):437-41. PubMed ID: 17956584
[TBL] [Abstract][Full Text] [Related]
7. Not all intravenous immunoglobulin preparations are equally well tolerated.
Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
[TBL] [Abstract][Full Text] [Related]
9. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
10. Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells.
Issekutz AC; Rowter D; Miescher S; Käsermann F
Clin Immunol; 2015 Oct; 160(2):123-32. PubMed ID: 25982320
[TBL] [Abstract][Full Text] [Related]
11. Variations in serum hemoglobin, albumin, and electrolytes in patients receiving intravenous immunoglobulin therapy: a real clinical threat?
Mignogna MD; Fortuna G; Ruoppo E; Adamo D; Leuci S; Fedele S
Am J Clin Dermatol; 2007; 8(5):291-9. PubMed ID: 17902731
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases.
Graf J; Ingwersen J; Lepka K; Albrecht P; Hartung HP; Ringelstein M; Aktas O
Acta Neurol Scand; 2019 Oct; 140(4):290-295. PubMed ID: 31269227
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study.
Melamed IR; Borte M; Trawnicek L; Kobayashi AL; Kobayashi RH; Knutsen A; Gupta S; Smits W; Pituch-Noworolska A; Strach M; Pulka G; Ochs HD; Moy JN
Eur J Pharm Sci; 2018 Jun; 118():80-86. PubMed ID: 29522908
[TBL] [Abstract][Full Text] [Related]
14. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
15. Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early-onset sepsis.
Christensen RD; Brown MS; Hall DC; Lassiter HA; Hill HR
J Pediatr; 1991 Apr; 118(4 Pt 1):606-14. PubMed ID: 1901083
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.
Petrides PE; Gisslinger H; Steurer M; Linkesch W; Krumpl G; Schüller A; Widmann R
Clin Ther; 2009 Feb; 31(2):386-98. PubMed ID: 19302911
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
Kishiyama JL; Valacer D; Cunningham-Rundles C; Sperber K; Richmond GW; Abramson S; Glovsky M; Stiehm R; Stocks J; Rosenberg L; Shames RS; Corn B; Shearer WT; Bacot B; DiMaio M; Tonetta S; Adelman DC
Clin Immunol; 1999 May; 91(2):126-33. PubMed ID: 10227804
[TBL] [Abstract][Full Text] [Related]
18. A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories.
Ensom MH; Stephenson MD
Hum Reprod; 2011 Sep; 26(9):2283-8. PubMed ID: 21771770
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin-associated acute renal failure: case series and literature review.
Itkin YM; Trujillo TC
Pharmacotherapy; 2005 Jun; 25(6):886-92. PubMed ID: 15927908
[TBL] [Abstract][Full Text] [Related]
20. The effect of Intravenous Immunoglobulin (IVIG) on \textit{ex vivo} activation of human leukocytes.
Basyreva LY; Brodsky IB; Gusev AA; Zhapparova ON; Mikhalchik EV; Gusev SA; Shor DB; Dahan S; Blank M; Shoenfeld Y
Hum Antibodies; 2016; 24(3-4):39-44. PubMed ID: 28128763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
